FDA Advisory Committee to review VIVUS' NDA for Qnexa

VIVUS, Inc. (Nasdaq: VVUS) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is tentatively scheduled to review the Company's New Drug Application (NDA) for Qnexa® for the treatment of obesity on July 15, 2010.  VIVUS submitted its NDA on December 28, 2009 seeking approval to market Qnexa in the United States; on March 1, 2010, the FDA accepted the NDA filing for review.  The target date for the FDA to complete its review of the Qnexa NDA is October 28, 2010.  

"Review by the Advisory Committee represents a critical milestone for Qnexa and for VIVUS.  We believe Qnexa, if approved, could become a treatment option for obese patients," stated Leland Wilson, chief executive officer of VIVUS.  "We look forward to discussing the efficacy and safety data of Qnexa with the members of the Endocrinologic and Metabolic Drugs Advisory Committee."